Therapeutic potential of thymoquinone against anti-tuberculosis drugs induced liver damage

Environmental Toxicology and Pharmacology

Volumn 36, Issue 3, 2013, Pages 779-786

  Jaswal, Amita ^a   Sinha, Neelu ^a   Bhadauria, Monika ^a   Shrivastava, Sadhana ^a   Shukla, Sangeeta ^a  

^a JIWAJI UNIVERSITY   (India)

Author keywords

Anti TB drugs; Antioxidant activity; Biochemical parameters; Histopathology; Thymoquinone

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CREATININE; CYTOCHROME P450; ETHAMBUTOL; ISONIAZID; LIVER ENZYME; PYRAZINAMIDE; RIFAMPICIN; SILYMARIN; THYMOQUINONE; TUBERCULOSTATIC AGENT; UREA; URIC ACID;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE CONTROL; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HISTOLOGY; HYPERTRANSAMINASEMIA; KIDNEY PARENCHYMA; LIPID PEROXIDATION; LIVER; LIVER FUNCTION; LIVER PROTECTION; LIVER TOXICITY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXIC HEPATITIS; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

RATTUS;

ANTI-TB DRUGS; ANTIOXIDANT ACTIVITY; BIOCHEMICAL PARAMETERS; HISTOPATHOLOGY; THYMOQUINONE;

ANALYSIS OF VARIANCE; ANIMALS; ANTITUBERCULAR AGENTS; BENZOQUINONES; BLOOD CHEMICAL ANALYSIS; DRUG-INDUCED LIVER INJURY; ETHAMBUTOL; FEMALE; ISONIAZID; KIDNEY; LIPID PEROXIDATION; LIPIDS; LIVER; LIVER FUNCTION TESTS; PYRAZINAMIDE; RATS; RATS, SPRAGUE-DAWLEY; RIFAMPIN; SUPEROXIDE DISMUTASE;

EID: 84882780015     PISSN: 13826689     EISSN: 18727077     Source Type: Journal    
DOI: 10.1016/j.etap.2013.07.010     Document Type: Article

References (44)

1. Aebi H. Cabalase in vitro. Methods in Enzymology 1984, 105:121-126.
2. Ahmed W.A., Hassan S.A., Galeb F.M., El-Taweel M.A., Abu-Bedair F.A. The in vitro promising therapeutic activity of thymoquinone on hepatocellular carcinoma (HepG2) cell line. Global Veterinaria 2008, 2(5):233-241.
3. Ali B.H., Blunden G. Pharmacological and toxicological properties of Nigella sativa. Phytotherapy Research 2003, 17:299-305.
4. Ali Z.Y. Biochemical evaluation of some natural products against toxicity induced by anti-tubercular drugs in rats. New York Science Journal 2012, 5(10):69-80.
5. Ansari J.A. Therapeutic approaches in management of drug induced hepatotoxicity. Journal of Biological Sciences 2010, 10:386-395.
6. Arulselvan P., Subramanian S.P. Beneficial effects of Murraya koenigii leaves on antioxidant defense system and ultra structural changes of pancreatic β-cells in experimental diabetes in rats. Chemico-Biological Interactions 2007, 165:155-164.
7. Badary O.A., Taha R.A., Gamel-El Din A.M., Abdel-Wahab M.H. The in vitro antixoidant and pro-oxidant action of thymoquinone and tert butylhydroquinone. Egyptian Journal of Biochemistry and Molecular Biology 2002, 20:1-16.
8. Baginski E.S., Foa P.P., Zak B. Glucose-6-phosphate. Methods of Enzymatic Analysis 1974, 115. VCH, Weinheim. 2nd ed. H.E. Bergmeyer (Ed.).
9. 4 induced hepatotoxicity. Journal of Ethnopharmacology 2007, 111:560-566.
10. Effenberger K., Breyer S., Schobert R. Terpene conjugates of the Nigella sativa seed-oil constituent thymoquinone with enhanced efficacy in cancer cells. Chemistry & Biodiversity 2010, 7:129-139.
11. Ellard G.A., Gammon P.T. Pharmacokinetics of isoniazid metabolism in man. Journal of Pharmacokinetics and Biopharmaceutics 1976, 4:83-113.
12. Eseyin O., Ebong P., Eyong E., Awofisayo O., Agboke A. Effect of Telfairia occidentalis on oral glucose tolerancein rats. African Journal of Pharmacy and Pharmacology 2010, 4(6):368-372.
13. Georgieva N., Gadjeva V., Tolekova A. New isonicotinoylhydrazones with ssa protect against oxidative hepatic injury of isoniazid. Trakia Journal of Sciences 2004, 2:37-43.
14. Hassan S.A., Ahmed W.A., Galeb F.M., El-Taweel M.A., Abu-Bedair F.A. In vitro challenge using thymoquinone on hepatocellular carcinoma (HepG2) cell line. Iranian Journal of Pharmaceutical Research 2008, 7(4):283-290.
15. Houghton P.J., Zarka R., de las Heras B., Hoult J.R.S. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Medica 1995, 61:33-36.
16. Huang Y.S., Chern H.D., Su W.J., Wu J.C., Chang S.C., Chiang C.H. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37:924-930.
17. Hussain T., Gupta R.K., Sweety K., Khan M.S., Hussain M.S., Arif M., Hussain A., Faiyazuddin M., Rao C.V. Evaluation of antihepatotoxic potential of Solanum xanthocarpum fruit extract against antitubercular drugs induced hepatopathy in experimental rodents. Asian Pacific Journal of Tropical Biomedicine 2012, 454-460.
18. Jeyakumar R., Rajesh R., Meena B., Rajaprabhu D., Ganesan B., Buddhan S., Anandan R. Antihepatotoxic effect of Picrorhiza kurroa on mitochondrial defense system in antitubercular drugs (isoniazid and rifampicin)-induced hepatitis in rats. Journal of Medicinal Plant Research 2008, 2(1):17-19.
19. Kalra B.S., Aggarwal S., Khurana N., Gupta A. Effect of cimetidine on hepatotoxicity induced by isoniazidrifampicin combination in rabbits. Indian Journal of Gastroenterology 2007, 26:18-21.
20. Kim S.H., Kim S.H., Lee J.H., Lee B.H., Kim Y.S., Park J.S., Jee Y.K. Polymorphisms in drug transporter genes (ABCB1, SLCO1B1 and ABCC2) and hepatitis induced by antituberculosis drugs. Tuberculosis 2012, 92:100-104.
21. Manonmani G., Bhavapriya V., Kalpana S., Govindasamy S., Apparanantham T. Antioxidant activity of Cassia fistula (Linn.) flowers in alloxan induced diabetic rats. Journal of Ethnopharmacology 2005, 97:39-42.
22. Mishra H.P., Fridovich I. The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. Journal of Biological Chemistry 1972, 247:3170-3175.
23. Nahar B.L., Mosharrof H.A.K.M., Monirul I.M., Saha D.R. A comparative study on the adverse effects of two anti-tuberculosis drugs regimen in initial two-month treatment period. Bangladesh Journal of Pharmacology 2006, 1:51-57.
24. Nili-Ahmadabadi A., Tavakoli F., Hasanzadeh G.R., Rahimi H.R., Sabzevari O. Protective effect of pretreatment with thymoquinone against Aflatoxin B1 induced liver toxicity in mice. Daru 2011, 19:4.
25. Nortadas R., Barata J. Fulminant hepatitis during self medication with conjugated linoleic acid. Annals of Hepatology 2012, 11(2):265-267.
26. Punitha I.S.R., Shirwaikar A., Shirwaikar A. Antidiabetic activity of benzyl tetra isoquinoline alkaloid berberine in streptozotocin-nicotinamide induced type 2 diabetic rats. Diabetologia Croatica 2005, 34:117-128.
27. Ravi V., Patel S.S., Verma N.K., Dutta D., Saleem T.S. Hepatoprotective activity of Bombax ceiba Linn against isoniazid and rifampicin-induced toxicity in experimental rats. International Journal of Applied Research in Natural Products 2010, 3(3):19-26.
28. Ravishah S., Manjula S.N., Mruthunjaya K., Krishnanand P., Pramod C.K.N., Madhu R.M., Sweety J., Basirian M. Hepatoprotective activity of roots of Lawsonia inermis against paracetamol and antitubercular drugs induced hepatotoxicity in rats. International Journal of Pharmaceutics 2012, 2(2):306-316.
29. Reitman S., Frankel S.A. Colorimetric method for the determination of serum glutamic oxalacetic and glutamic piruvic transaminases. American Journal of Clinical Pathology 1957, 28:56-63.
30. Riley V. Adaptation of orbital bleeding technique to rapid serial blood studies. Proceedings of the Society for Experimental Biology and Medicine 1960, 104:751-754.
31. Seth P.K., Tangari K.K. Biochemical effects of newer salicylic acid congenesis. Journal of Pharmacy and Pharmacology 1996, 18:831.
32. Shakya A.K., Sharma N., Saxena M., Shrivastava S., Shukla S. Evaluation of the antioxidant and hepatoprotective effect of Majoon-e-Dabeed-ul-ward against carbon tetrachloride induced liver injury. Experimental and Toxicologic Pathology 2012, 64(7-8):767-773.
33. Shapiro M.A., Lewis J.H. Causality assessment of drug induced hepatotoxicity: promises and pitfalls. Clinical Liver Disease 2007, 11:477-505.
34. Sharma S.K., Krishnamurthy C.R. Production of lipid peroxides of brain. Journal of Neurochemistry 1968, 15:147-149.
35. Shen C., Zhang H., Zhang G., Meng Q. Isoniazid-induced hepatotoxicity in rat hepatocytes of gel entrapment culture. Toxicology Letters 2006, 167:66-74.
36. Snedecor G.W., Cochran W.G. Statistical Method 1989, 217-236. Affiliated East-West Press, Ames, IA. 8th ed.
37. Solangi G.A., Zuberi B.F., Shaikh S., Shaikh W.M. Pyrazina-mide-induced hyperuricemia in patients taking anti-tuberculosis therapy. Journal of the College of Physicians and Surgeons 2004, 14:136-138.
38. Swamy A.H.M.V., Kulkarni R.V., Thippeswamy A.H.M., Koti B.C., Gore A. Evaluation of hepatoprotective activity of Cissus quandrangularis stem extract against isonizid-induced liver damage in rats. Indian Journal of Pharmacology 2010, 42(6):397-400.
39. Tasduq S.A., Kaisar P., Gupta D.K., Kapahi B.K., Maheshwari H.S., Jyotsna S. Protective effect of a 50% hydroalcoholic fruit extract of Emblica officinalis against anti-tuberculosis drugs induced liver toxicity. Phytotherapy Research 2005, 19:193-197.
40. Tasduq S.A., Kaiser P., Sharma S.C., Johri R.K. Potentiation of isoniazid-induced liver toxicity by rifampicin in a combinational therapy of antitubercular drugs (rifampicin, isoniazid and pyrazinamide) in Wister rats: a toxicity profile study. Hepatology Research 2007, 37(10):845-853.
41. Thomas B.S., Wong L.T., Zeitz W., Solomonraj G. Isoniazid metabolism in the rabbit, and the effect of rifampin pretreatment. Research Communications in Chemical Pathology and Pharmacology 1981, 33:235-247.
42. Valizadeh N., Zakeri H.R., Amin ansafi G., Shafiee A., Sarkhail P., Heshmat R., Sereshti H., Larijani B. Impact of Black seed (Nigella sativa) extract on bone turnover markers in postmenopausal women with osteoporosis. Daru 2010, 1:20-25.
43. Yue J., Peng R. Does CYP2E1 play a major role in the aggravation of isoniazid toxicity by rifampicin in human hepatocytes?. British Journal of Pharmacology 2009, 157(3):331-333.
44. Yue J., Peng R.X., Yang J., Kong R., Liu J. CYP2E1 mediated isoniazid-induced hepatotoxicity in rats. Acta Pharmacologica Sinica 2004, 25:699-704.